Welcome to our dedicated page for Skye Bioscience SEC filings (Ticker: SKYE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Skye Bioscience, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing G-protein-coupled receptor modulators for obesity and metabolic health. Form 8-K reports cover financial results, corporate updates, Reg FD clinical communications for nimacimab and the CBeyond program, and material events tied to executive transitions, equity compensation and Nasdaq listing-compliance matters.
The company's proxy materials address annual meeting voting, director elections, executive compensation, pay-versus-performance tables, equity awards and incentive-plan governance. Compensation-related filings also describe stock-option repricing under Skye equity incentive plans and related common-stock disclosures.
Skye Bioscience director Karen L. Smith received a grant of stock options covering 75,000 shares of Common Stock. The options have an exercise price of $0.615 per share and expire on March 31, 2036. They vest in equal monthly installments over the one-year period beginning March 31, 2026. Following this grant, she holds 75,000 stock options directly.
Skye Bioscience Chief Scientific Officer Christopher Twitty reported compensation-related stock option changes with no open-market trading of common shares. On March 31, 2026, he received several new stock option grants, including 200,000 options, 150,000 options, and 75,000 options to buy common stock at exercise prices of $0.615 or $0.610 per share.
The filing also shows matching dispositions back to the company of older options with higher exercise prices ranging from $2.89 to $14.56, effectively repricing these awards. Footnotes explain that the board approved a one-time repricing to $0.615 per share for certain options and clarify multi-year monthly vesting schedules and a prior administrative vesting disclosure error.
Skye Bioscience director Annalisa Jenkins received a new stock option grant covering 75,000 shares of Common Stock. The option has an exercise price of $0.615 per share and expires on March 31, 2036. It vests in equal monthly installments over one year beginning March 31, 2026.
Skye Bioscience Chief Operating Officer Diep Tuan Tu filed an amended insider ownership report to add previously omitted equity awards. The filing lists restricted stock unit awards for up to 72,833 shares that vest in stages when Skye’s market capitalization reaches $125M, $250M, $400M and at an exit of $500M or greater, with acceleration upon a change in control. It also details an additional RSU grant vesting in three equal annual installments from December 14, 2021. Several stock option grants are disclosed, including options over 8,000 shares at an exercise price of $11.25 expiring in 2030, and options over 7,080, 22,021 and 9,194 shares at $3.50–$14.50 per share expiring between 2031 and 2033, all subject to service-based vesting and full vesting on a change in control.
Skye Bioscience director Deborah H. Charych received a stock option grant for 75,000 shares of Common Stock. The option has an exercise price of $0.6150 per share, expires on March 31, 2036, and was awarded at no cost as a compensation grant.
The stock option vests in equal monthly installments over a one-year period beginning March 31, 2026. Following this grant, Charych holds 75,000 stock options directly, giving her the right to buy an equivalent number of common shares if she chooses to exercise in the future.
Skye Bioscience director Paul A. Grayson received a grant of stock options for 75,000 shares of Common Stock. The options have an exercise price of $0.615 per share and expire on March 31, 2036. The award vests in equal monthly installments over one year beginning March 31, 2026, and represents his full reported option holdings from this filing.
Skye Bioscience director Andrew J. Schwab received a grant of stock options covering 75,000 shares of common stock at an exercise price of $0.615 per share. The options were awarded at no upfront cost, expire on March 31, 2036, and vest in equal monthly installments over one year beginning March 31, 2026. This filing reflects a compensation-related equity award rather than an open-market purchase or sale of shares.
Skye Bioscience Chief Operating Officer Diep Tuan Tu reported a board-approved, one-time repricing of several stock option awards effective March 31, 2026. Existing options with exercise prices between $2.89 and $14.56 per share were surrendered and replaced with new options for the same share amounts at a $0.615 exercise price, matching the closing price on the repricing date.
The grants include, among others, a 150,000-share option expiring on February 25, 2035 and additional options for 75,000, 22,021, 9,194, 8,000 and 7,080 shares at the same $0.615 exercise price. These options generally vest in equal monthly installments over four years from their original vesting start dates and become fully vested upon a change in control. The filing reflects compensation-related option adjustments, not open-market purchases or sales of common stock.
Skye Bioscience reported that Chief Executive Officer Punit Dhillon had several existing stock option grants repriced effective March 31, 2026. Options covering blocks such as 650,000 and 250,000 shares were canceled and replaced with new options for the same share amounts, now carrying a $0.615 per-share exercise price, which matches the closing stock price on the repricing date. According to the disclosure, all other terms of each stock option remain unchanged.
One grant is already fully vested, while others continue to vest in equal monthly installments over four-year periods tied to original grant dates in 2023 and 2024. Each of these options becomes fully vested if there is a change in control of the company. These are compensation-related derivative transactions only and do not involve any open-market purchases or sales of common shares.
Skye Bioscience, Inc. received a Nasdaq deficiency letter on March 17, 2026 because its common stock’s closing bid price has stayed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1) for The Nasdaq Global Market.
The stock continues trading under the “SKYE” symbol, and Skye has 180 calendar days, until September 14, 2026, to regain compliance, including the option to complete any reverse stock split at least ten business days before that date. If the bid price closes at or above $1.00 for at least 10 consecutive business days before that deadline, Nasdaq staff will confirm compliance. Skye may qualify for a second 180-day period on The Nasdaq Capital Market if it meets other listing standards and commits to curing the deficiency, but there is no assurance it will regain or maintain compliance.